Short answer
MESA LABORATORIES INC /CO/ (MLAB) filed an 8-K current report with the SEC on November 9, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Press release covers Mesa Laboratories’ fiscal Q2 and first-half results through September 30, 2026.
MESA LABORATORIES INC /CO/ 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release covers Mesa Laboratories’ fiscal Q2 and first-half results through September 30, 2026
- Investors should review Exhibit 99.1 for revenue, earnings, margins, guidance and segment performance details
Item EX-99.1 · Exhibit EX-99.1
- 2Q27 revenue $62.3M, up 2.6%; adjusted EBITDA $17.3M, margin 27.8% versus 23.5%, signaling substantial operating leverage
- SDC revenue rose 14.6% to $25.3M, while BPD and Clinical Genomics declined 8.2% and 8.8%, respectively
- First FY27 guidance: revenue $250M to $255M and adjusted EBITDA $66M to $68M, excluding restructuring charges
- Savings Plan targets $9.3M annualized cost reductions, with $4.3M reinvestment and $2.6M to $3.4M restructuring charges
- Debt repayment of $11.4M reduced net leverage to 1.75; new $40M share repurchase authorization expires December 31, 2028
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other MESA LABORATORIES INC /CO/ 8-K filings
Get the next MLAB 8-K as it lands
Follow MLAB for push alerts, or ask the research agent what this filing means.